KR20020084066A - 알러지성 질환의 치료 방법 및 그를 위한 조성물 - Google Patents
알러지성 질환의 치료 방법 및 그를 위한 조성물 Download PDFInfo
- Publication number
- KR20020084066A KR20020084066A KR1020027006409A KR20027006409A KR20020084066A KR 20020084066 A KR20020084066 A KR 20020084066A KR 1020027006409 A KR1020027006409 A KR 1020027006409A KR 20027006409 A KR20027006409 A KR 20027006409A KR 20020084066 A KR20020084066 A KR 20020084066A
- Authority
- KR
- South Korea
- Prior art keywords
- bacteria
- antigen
- administered
- composition
- bacterial species
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 60
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- 208000010668 atopic eczema Diseases 0.000 title claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 5
- 230000000172 allergic effect Effects 0.000 title description 4
- 241000894006 Bacteria Species 0.000 claims abstract description 84
- 206010020751 Hypersensitivity Diseases 0.000 claims abstract description 11
- 230000007815 allergy Effects 0.000 claims abstract description 9
- 239000006041 probiotic Substances 0.000 claims abstract description 3
- 230000000529 probiotic effect Effects 0.000 claims abstract description 3
- 235000018291 probiotics Nutrition 0.000 claims abstract description 3
- 230000003385 bacteriostatic effect Effects 0.000 claims abstract 4
- 239000000427 antigen Substances 0.000 claims description 46
- 102000036639 antigens Human genes 0.000 claims description 46
- 108091007433 antigens Proteins 0.000 claims description 46
- 239000013566 allergen Substances 0.000 claims description 41
- 241000894007 species Species 0.000 claims description 34
- 230000001580 bacterial effect Effects 0.000 claims description 33
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 24
- 208000026935 allergic disease Diseases 0.000 claims description 20
- 235000013305 food Nutrition 0.000 claims description 16
- 241000186660 Lactobacillus Species 0.000 claims description 14
- 241000124008 Mammalia Species 0.000 claims description 12
- 229940039696 lactobacillus Drugs 0.000 claims description 12
- 108060003951 Immunoglobulin Proteins 0.000 claims description 10
- 102000004388 Interleukin-4 Human genes 0.000 claims description 10
- 108090000978 Interleukin-4 Proteins 0.000 claims description 10
- 102000018358 immunoglobulin Human genes 0.000 claims description 10
- 210000003296 saliva Anatomy 0.000 claims description 9
- 102100037850 Interferon gamma Human genes 0.000 claims description 8
- 108010074328 Interferon-gamma Proteins 0.000 claims description 8
- 244000199866 Lactobacillus casei Species 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 210000002966 serum Anatomy 0.000 claims description 7
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 230000000977 initiatory effect Effects 0.000 claims description 6
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 208000006673 asthma Diseases 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 239000004816 latex Substances 0.000 claims description 5
- 229920000126 latex Polymers 0.000 claims description 5
- 206010002198 Anaphylactic reaction Diseases 0.000 claims description 4
- 201000004624 Dermatitis Diseases 0.000 claims description 4
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 4
- 230000036783 anaphylactic response Effects 0.000 claims description 4
- 208000003455 anaphylaxis Diseases 0.000 claims description 4
- 230000000968 intestinal effect Effects 0.000 claims description 4
- 229940017800 lactobacillus casei Drugs 0.000 claims description 4
- 208000004262 Food Hypersensitivity Diseases 0.000 claims description 3
- 241000238631 Hexapoda Species 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 235000020932 food allergy Nutrition 0.000 claims description 3
- 230000035515 penetration Effects 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 231100000614 poison Toxicity 0.000 claims description 3
- 239000002574 poison Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 230000001932 seasonal effect Effects 0.000 claims description 3
- 230000035945 sensitivity Effects 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims description 2
- 206010016946 Food allergy Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 208000030961 allergic reaction Diseases 0.000 claims 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 claims 1
- 238000003018 immunoassay Methods 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 239000007909 solid dosage form Substances 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 25
- 230000004044 response Effects 0.000 description 20
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 9
- 238000010171 animal model Methods 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108010058846 Ovalbumin Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000005875 antibody response Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 206010051841 Exposure to allergen Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 235000013618 yogurt Nutrition 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 241000588921 Enterobacteriaceae Species 0.000 description 2
- 206010073310 Occupational exposures Diseases 0.000 description 2
- 229940037003 alum Drugs 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 239000003659 bee venom Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000002222 downregulating effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 231100000675 occupational exposure Toxicity 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 206010061958 Food Intolerance Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000013572 airborne allergen Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 235000016046 other dairy product Nutrition 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 210000003752 saphenous vein Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/07—Bacillus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6866—Interferon
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/125—Casei
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/335—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Lactobacillus (G)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Otolaryngology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPQ4158A AUPQ415899A0 (en) | 1999-11-19 | 1999-11-19 | Compositions for and methods of treatment of allergic diseases |
| AUPQ4158 | 1999-11-19 | ||
| PCT/AU2000/001414 WO2001037865A1 (en) | 1999-11-19 | 2000-11-20 | Compositions and methods for treatment of allergic disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20020084066A true KR20020084066A (ko) | 2002-11-04 |
Family
ID=3818302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020027006409A KR20020084066A (ko) | 1999-11-19 | 2000-11-20 | 알러지성 질환의 치료 방법 및 그를 위한 조성물 |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1229930A4 (de) |
| JP (1) | JP2003514869A (de) |
| KR (1) | KR20020084066A (de) |
| CN (1) | CN1391480A (de) |
| AU (1) | AUPQ415899A0 (de) |
| BR (1) | BR0015698A (de) |
| CA (1) | CA2391499A1 (de) |
| HK (1) | HK1049115A1 (de) |
| WO (1) | WO2001037865A1 (de) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101311989B1 (ko) * | 2010-11-17 | 2013-09-26 | 주식회사한국야쿠르트 | 면역 조절 및 강화 효능을 갖는 락토바실러스 카제이 에이치와이7211를 유효성분으로 함유하는 제품 |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ID29150A (id) | 1999-01-15 | 2001-08-02 | Entpr Ireland Cs | Penggunaan lactobacillus salivarius |
| FI110668B (fi) * | 2000-06-20 | 2003-03-14 | Aboatech Ab Oy | Probioottien käyttö atooppisten sairauksien primaariseen ehkäisyyn |
| PE20030283A1 (es) * | 2001-07-26 | 2003-05-01 | Alimentary Health Ltd | Cepas de lactobacillus casei |
| GB0124580D0 (en) | 2001-10-12 | 2001-12-05 | Univ Reading | New composition |
| JP4212838B2 (ja) | 2002-06-26 | 2009-01-21 | カルピス株式会社 | 抗アレルギー剤 |
| AU2004233658B2 (en) * | 2003-03-13 | 2009-10-29 | Kirin Holdings Kabushiki Kaisha | Antiallergic composition |
| JP4712289B2 (ja) * | 2003-08-26 | 2011-06-29 | 株式会社エイ・エル・エイ | 免疫促進用組成物 |
| JP4591810B2 (ja) * | 2003-09-19 | 2010-12-01 | 日之出産業株式会社 | 花粉症アレルギー性鼻炎抑制用点鼻組成物 |
| AU2004298384A1 (en) * | 2003-12-17 | 2005-06-30 | N.V. Nutricia | Lactic acid producing bacteria and lung function |
| US7955834B2 (en) | 2004-06-03 | 2011-06-07 | Biogaia Ab | Method for improved breast milk feeding to reduce the risk of allergy |
| TWI356680B (en) * | 2007-01-05 | 2012-01-21 | Promd Biotech Co Ltd | Anti-allergy lactic acid bacteria |
| CN102657260B (zh) * | 2007-06-21 | 2013-08-21 | 东宇生物科技股份有限公司 | 抗过敏的乳酸菌 |
| CN101328468B (zh) * | 2007-06-21 | 2012-05-23 | 东宇生物科技股份有限公司 | 抗过敏的乳酸菌 |
| EP2065048A1 (de) * | 2007-11-30 | 2009-06-03 | Institut Pasteur | Verwendung eines L.-casei-Stammes zur Herstellung einer Zusammensetzung zur Mastzellenaktivierung |
| PT2244734T (pt) | 2008-02-01 | 2016-08-05 | Murdoch Childrens Res Inst | Método para induzir tolerância a um alérgeno |
| WO2012021432A2 (en) | 2010-08-10 | 2012-02-16 | R.P Scherer Technologies, Llc | Process of manufacturing a stable softgel capsule containing microencapsulated probiotic bacteria |
| EP3738599B1 (de) * | 2018-01-12 | 2023-12-27 | GI Innovation, Inc. | Zusammensetzung mit probiotika und polypeptid mit bindungsaffinität für ige und verwendung davon |
| CN111296842B (zh) * | 2020-02-14 | 2021-01-05 | 赵一鸣 | 一种具有抗敏作用的益生菌组合物 |
| CN112375722B (zh) * | 2021-01-18 | 2021-04-13 | 山东中科嘉亿生物工程有限公司 | 一种改善过敏的干酪乳杆菌lc-12及其产品、应用 |
| WO2024081219A1 (en) | 2022-10-14 | 2024-04-18 | Csp Technologies, Inc. | Container and method for storing and stabilizing moisture sensitive products |
| CN117085046A (zh) * | 2023-10-20 | 2023-11-21 | 潍坊君薇生物科技有限责任公司 | 嗜酸乳杆菌ls001后生元及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5946488B2 (ja) | 1978-08-07 | 1984-11-13 | 極東脂肪酸株式会社 | アレルギ−反応抑制剤 |
| JPS5946491B2 (ja) | 1979-03-14 | 1984-11-13 | 極東脂肪酸株式会社 | 喘息治療剤 |
| JPH07265064A (ja) | 1993-11-23 | 1995-10-17 | Taketoshi Yamada | 腸内細菌叢改善組成物 |
| JPH092959A (ja) | 1995-06-16 | 1997-01-07 | Yakult Honsha Co Ltd | ＩｇＥ抗体産生抑制剤および抗アレルギー剤 |
| EP0904784A1 (de) * | 1997-09-22 | 1999-03-31 | N.V. Nutricia | Probiotisches Ernährungspräparat |
| JPH11199495A (ja) * | 1998-01-10 | 1999-07-27 | Nichinichi Seiyaku Kk | 腸溶性カプセルを用いた抗アレルギー剤 |
| IT1298918B1 (it) * | 1998-02-20 | 2000-02-07 | Mendes Srl | Uso di batteri dotati di arginina deiminasi per indurre apoptosi e/o ridurre una reazione infiammatoria e composizioni farmaceutiche |
| JP4074006B2 (ja) * | 1998-06-24 | 2008-04-09 | アサマ化成株式会社 | ＩｇＥ抗体産生抑制物質の製造方法並びにそれを用いた食品 |
-
1999
- 1999-11-19 AU AUPQ4158A patent/AUPQ415899A0/en not_active Abandoned
-
2000
- 2000-11-20 WO PCT/AU2000/001414 patent/WO2001037865A1/en active Search and Examination
- 2000-11-20 JP JP2001539479A patent/JP2003514869A/ja not_active Withdrawn
- 2000-11-20 BR BR0015698-1A patent/BR0015698A/pt not_active IP Right Cessation
- 2000-11-20 EP EP00975685A patent/EP1229930A4/de not_active Withdrawn
- 2000-11-20 CN CN00815855A patent/CN1391480A/zh active Pending
- 2000-11-20 KR KR1020027006409A patent/KR20020084066A/ko not_active Application Discontinuation
- 2000-11-20 CA CA002391499A patent/CA2391499A1/en not_active Abandoned
-
2003
- 2003-02-11 HK HK03100999.8A patent/HK1049115A1/zh unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101311989B1 (ko) * | 2010-11-17 | 2013-09-26 | 주식회사한국야쿠르트 | 면역 조절 및 강화 효능을 갖는 락토바실러스 카제이 에이치와이7211를 유효성분으로 함유하는 제품 |
Also Published As
| Publication number | Publication date |
|---|---|
| HK1049115A1 (zh) | 2003-05-02 |
| CA2391499A1 (en) | 2001-05-31 |
| BR0015698A (pt) | 2002-07-23 |
| WO2001037865A1 (en) | 2001-05-31 |
| EP1229930A1 (de) | 2002-08-14 |
| EP1229930A4 (de) | 2004-09-22 |
| CN1391480A (zh) | 2003-01-15 |
| JP2003514869A (ja) | 2003-04-22 |
| AUPQ415899A0 (en) | 1999-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20020084066A (ko) | 알러지성 질환의 치료 방법 및 그를 위한 조성물 | |
| US11433106B2 (en) | Compositions comprising bacterial strains | |
| TWI797058B (zh) | 包含細菌菌株之組合物 | |
| Bischoff et al. | Gastrointestinal food allergy: new insights into pathophysiology and clinical perspectives | |
| Bashir et al. | Toll-like receptor 4 signaling by intestinal microbes influences susceptibility to food allergy | |
| Scurlock et al. | Pediatric food allergy and mucosal tolerance | |
| Daniel et al. | Modulation of allergic immune responses by mucosal application of recombinant lactic acid bacteria producing the major birch pollen allergen Bet v 1 | |
| AU2009208390B2 (en) | A method of inducing tolerance to an allergen | |
| Srivastava et al. | Efficacy and immunological actions of FAHF-2 in a murine model of multiple food allergies | |
| Huber et al. | Immunostimulation by bacterial components: II. Efficacy studies and meta-analysis of the bacterial extract OM-89 | |
| Kulis et al. | Oral immunotherapy for food allergy: clinical and preclinical studies | |
| Banche et al. | Improvement of clinical response in allergic rhinitis patients treated with an oral immunostimulating bacterial lysate: in vivo immunological effects | |
| RU2197989C2 (ru) | ПРИМЕНЕНИЕ Mycobacterium vaccae ДЛЯ РЕГУЛЯЦИИ ПО ТИПУ ОТРИЦАТЕЛЬНОЙ ОБРАТНОЙ СВЯЗИ Th2-АКТИВНОСТИ ИММУННОЙ СИСТЕМЫ | |
| Ranallo et al. | Oral administration of live Shigella vaccine candidates in rhesus monkeys show no evidence of competition for colonization and immunogenicity between different serotypes | |
| Christensen et al. | Low-dose oral tolerance due to antigen in the diet suppresses differentially the cholera toxin-adjuvantized IgE, IgA and IgG response | |
| Talavera et al. | Formulation in tablets of a cholera whole cells inactivated vaccine candidate | |
| AU782689B2 (en) | Compositions and methods for treatment of allergic disorders | |
| US20040198696A1 (en) | Agent and food for inhibiting IgE antibody | |
| Chudzik-Kozłowska et al. | BALB/C mice as a model for immunogenicity testing of food proteins on the example of egg ovalbumin | |
| KR101275227B1 (ko) | 중증근무력증 예방, 개선 또는 치료용 조성물 | |
| Hassoba et al. | Anti-Allergy Agents, from Past to Future | |
| McClemens | The effect of Lactobacillus reuteri on host immune and cell alterations during an enteric parasitic infection | |
| Wood et al. | Fasting before Intra-Gastric Dosing with Antigen Improves Intestinal Humoral Responses in Syrian Fasting before Intra-Gastric Dosing with Antigen Improves Intestinal Humoral Responses in Syrian Hamsters | |
| Wood et al. | Fasting before Intra-Gastric Dosing with Antigen Improves Intestinal Humoral Responses in Syrian Hamsters. Vaccines 2024, 12, 572 | |
| Nowak-Węgrzyn et al. | 14 Future Diagnostics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |